ENDRA Life Sciences Inc. Cash Flow Statement
NDRA|4 years of annual SEC 10-K data (FY2017-FY2020)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 4 fiscal years. All figures from audited SEC 10-K filings.
ENDRA Life Sciences Inc. used $11M in operating cash flow and negative free cash flow of $11M in FY2020.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -7.14 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|
| Net Income | -$11.7M | -$9.8M | -$5.4M | -$5.4M |
| Depreciation & Amortization | $99.3K | $68.3K | $61.5K | $61.5K |
| Operating Cash Flow | -$10.7M | -$7.7M | -$3.3M | -$3.3M |
| Capital Expenditures | $75.3K | $100.0K | $7.9K | $7.9K |
| Free Cash Flow | -$10.8M | -$7.8M | -$3.3M | -$3.3M |
| FCF Margin | - | -126376.4% | -941.0% | -941.0% |